At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 795 enrolled
Drug / intervention
Insulin Efsitora Alfa +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3, Parallel-Design, Open-Label, Randomized Control Study to Evaluate the Efficacy and Safety of LY3209590 Administered Weekly Using a Fixed Dose Escalation Compared to Insulin Glargine in Insulin-Naïve Adults With Type 2 Diabetes
In Brief
A Phase 3 clinical trial evaluating Insulin Efsitora Alfa and Insulin Glargine for Type 2 Diabetes and T2D. Completed, enrolled 795 participants across 71 sites in 4 countries.
Detailed Summary
The main purpose of this study is to determine the efficacy and safety of insulin efsitora alfa (LY3209590) administered weekly using a fixed dose escalation compared to insulin glargine in adults with type 2 diabetes (T2D) who are starting basal insulin therapy for the first time.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType 2 Diabetes, T2D
CountriesArgentina, Mexico, Puerto Rico, United States
Collaborators--
Timeline
Phase 3CompletedFinished
2023202420252026
First PostedDec 2022
Enrollment StartJan 2023
Primary CompletionJul 2024
TodayJul 2026
First PostedDec 22, 2022
Enrollment StartJan 14, 2023
Primary CompletionJul 19, 2024
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 3.5 years ago
Interventions
Insulin Efsitora Alfadrug
Administered SC
Insulin Glarginedrug
Administered SC